Suppr超能文献

酪氨酸酶介导的共轭作用用于在铁蛋白纳米颗粒上展示抗原

Tyrosinase-Mediated Conjugation for Antigen Display on Ferritin Nanoparticles.

作者信息

Rodrigues Margarida Q, Patão Sara, Thomaz Mónica, Nunes Tiago, Alves Paula M, Roldão António

机构信息

iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.

ITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal.

出版信息

Bioconjug Chem. 2024 Sep 27;35(10):1608-17. doi: 10.1021/acs.bioconjchem.4c00387.

Abstract

Ferritin (Ft) nanoparticles have become versatile platforms for displaying antigens, being a promising technology for vaccine development. While genetic fusion has traditionally been the preferred method for antigen display, concerns about improper folding and steric hindrance that may compromise vaccine efficacy or stability have prompted alternative approaches. Bioconjugation offers the advantage of preserving native protein structure and function, with recent advancements improving efficiency and specificity. In this study, we used tyrosinase (TYR) to bioconjugate the receptor binding domain of the SARS-CoV-2 spike protein, tagged with a tyrosine (RBD-Y), to native cysteines on Ft, resulting in RBD-Y-Ft nanoparticles. We quantified available cysteines on ferritin using Ellman's assay and monitored their reduction during the reactions. Denaturing analytics (via SDS-PAGE, Western blot, and LC-TOF-MS) confirmed the formation of RBD-Y-Ft monomers with an expected molecular weight of 46 kDa. Mass photometry and HPLC estimated a molecular weight of RBD-Y-Ft nanoparticles of 680 kDa, which was higher than that of nonfunctionalized ferritin (480 kDa), indicating successful binding of up to eight RBD-Y antigens per 24-mer Ft nanoparticle. This work enhances our understanding of how Ft nanoparticles can be engineered to present antigens, leveraging them as a robust scaffold for producing tailored-made candidate vaccines in a timely manner.

摘要

铁蛋白(Ft)纳米颗粒已成为展示抗原的通用平台,是疫苗开发的一项有前景的技术。虽然基因融合传统上一直是抗原展示的首选方法,但对可能损害疫苗效力或稳定性的错误折叠和空间位阻的担忧促使人们采用其他方法。生物共轭具有保留天然蛋白质结构和功能的优势,最近的进展提高了效率和特异性。在本研究中,我们使用酪氨酸酶(TYR)将标记有酪氨酸的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域(RBD-Y)与Ft上的天然半胱氨酸进行生物共轭,从而得到RBD-Y-Ft纳米颗粒。我们使用埃尔曼分析法对铁蛋白上可用的半胱氨酸进行了定量,并监测了它们在反应过程中的减少情况。变性分析(通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳、蛋白质免疫印迹和液相色谱-飞行时间质谱)证实形成了预期分子量为46 kDa的RBD-Y-Ft单体。质量光度法和高效液相色谱估计RBD-Y-Ft纳米颗粒的分子量为680 kDa,高于未功能化铁蛋白的分子量(480 kDa),这表明每个24聚体Ft纳米颗粒成功结合了多达八个RBD-Y抗原。这项工作增进了我们对如何设计Ft纳米颗粒以呈递抗原的理解,将其作为一种强大的支架,以便及时生产定制的候选疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c990/11487507/dbf8b455d023/bc4c00387_0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验